Drugs / Theliatinib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02601274 | Apr 2015 → Dec 2018 | cancer | Hutchison Medipharma Limited | Terminated | No outcome recorded |
| Phase 1 | NCT02601248 | Oct 2012 → Feb 2016 | cancer | Hutchison Medipharma Limited | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-11-01 | Hutchison Medipharma Limited | Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib hutch-med.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Theliatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02601274 ↗ |
| Known as | HMPL-309 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314410 ↗ |
| Known as | Xiliertinib | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314410 ↗ |
| Action | Inhibit | “EGFR tyrosine kinase inhibitor” NCT02601248 ↗ |
| Modality | Small molecule | — CHEMBL5314410 ↗ |
| Route | Oral | “oral,once daily” NCT02601248 ↗ |
| Target | EGFR | “EGFR tyrosine kinase inhibitor” NCT02601248 ↗ |